Exploratory analysis of liquid biopsy for the predictive factors associated with outcome of PD-1 Pathway Blockade in Multicenter Study

Exploratory analysis of liquid biopsy for the predictive factors associated with outcome of PD-1 Pathway Blockade in Multicenter Study - MRD-PD1 study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1032220559

Enrollment

100

Registered

2023-01-07

Start date

2023-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet the eligibility criteria of the most recent JCOG 1701 (to confirm the non-inferiority of survival of discontinuation of PD-1 pathway inhibitors versus their continuation in patients with advanced or recurrent non-small-cell lung cancer who have had no reccurence to PD-1 pathway inhibitors for 12 months or longer) protocol and who are not participating in JCOG 1701 Patients who have given their written consent to participate in this study Patients who are able to provide tumor tissue samples necessary for the study

Exclusion criteria

Exclusion criteria: Patients who do not meet the eligibility criteria in the most recent JCOG1701 protocol or are currently participating in JCOG1701

Design outcomes

Primary

Measure	Time frame
Evaluate MRD (minimum residual disease) by ctDNA (circulating tumor DNA) to find the biomarker for logterm effective of PD-1 pathway inhibitor.	—

Contacts

Public ContactYasushi Goto

Department of Thoracic Oncology, National Cancer Center Hospital

ygoto@ncc.go.jp+81-3-3542-2511

Outcome results